Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
|Articles|October 8, 2015
FDA Grants Breakthrough Therapy Designation to Lilly Cancer Drug
October 08, 2015.
Advertisement
FDA has granted Breakthrough Therapy Designation to Eli Lilly and Company's abemaciclib for patients with refractory hormone-receptor-positive advanced or metastatic breast cancer.
The Breakthrough Therapy Designation aims to expedite the development and review of drugs that are intended to treat a serious condition, and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
FDA's decision is based on data from the breast cancer cohort expansion of Lilly's Phase I trial, JPBA, which studied the efficacy and safety of abemaciclib in women with advanced or metastatic breast cancer.
Advertisement
Related to this article
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
MFN Is an Offer Pharma Can’t Refuse
4
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
5